Leapfrog Bio

Leapfrog Bio is a clinical-stage precision oncology company accelerating cancer drug development by identifying clinical-stage molecules that can be retargeted as directed therapies for cancers with undruggable driver mutations. The company’s lead program is a Phase 2 proof-of-concept trial evaluating a small molecule in three solid cancers with an unaddressed, but frequent, loss-of-function genetic mutation. The company’s Precision PGx Platform provides a repeatable and scalable in vitro system to identify existing small-molecule drugs that can be developed to treat cancers driven by loss-of-function mutations with a high probability of clinical success.